Search

Displaying results 1441 - 1450 of 10000 in total
  1. Drug

    Vitamin E

    go.drugbank.com/drugs/DB00163
    ApprovedInvestigationalNutraceuticalVet approved

    Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active[A176104]. … Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label].

    Synonyms: (2R,4'R,8'R)-α-tocopherol, (R,R,R)-α-tocopherolInternational brands: Aquasol E, Amino-Opti-E
  2. Drug

    Iloprost

    go.drugbank.com/drugs/DB01088
    ApprovedInvestigational

    [A263326] Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47.[L50146] It is a potent vasodilator with reported anti-thrombotic properties.

    Synonyms: (E)-(3aS, 4R, 5R, 6aS)-hexahydro-5-hydroxy-4-[(E)-(3S,4RS)­ 3-hydroxy-4-methyl-1-octen-6-ynyl]-Δ2(1H),Δ-pentalenevaleric acid, (5E)-[3aS,4R,5R,6aS)-5-Hydroxy-4-[(1E)-(3S,4RS)-3-hydroxy-4-methyloct-1-en-6-ynyl]-hexahydropentalen-2(1H)-ylidene]pentanoic acidProducts: VENTAVIS ®, İVİLOST 20 MCG/2 ML İV İNFÜZYON İÇİN ÇÖZELTİ İÇEREN AMPUL, 1 AMPUL
  3. Drug

    Alcaftadine

    go.drugbank.com/drugs/DB06766
    Approved

    Alcaftadine is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. This drug was approved in July 2010.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingProducts: LASTACAFT®, LASTACAFT % 0,25 GÖZ DAMLASI, ÇÖZELTİ, 1 ADET
  4. Drug

    Dalfopristin

    go.drugbank.com/drugs/DB01764
    Approved

    Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  5. Drug

    Pibrentasvir

    go.drugbank.com/drugs/DB13878
    ApprovedInvestigational

    Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940]. … In clinical trials, this combination therapy achieved SVR12 rate, or undetectable Hepatitis C for twelve or more weeks after the end of treatment, of ≥93% across genotypes 1a, 2a, 3a, 4, 5 and 6 [L940]

    Mixtures: MAVIRET® 100/40 MG TABLETAS RECUBIERTASCategories: P-glycoprotein inhibitors, P-glycoprotein substrates
  6. Drug

    Nadifloxacin

    go.drugbank.com/drugs/DB12447
    Investigational

    Nadifloxacin has been used in trials studying the treatment of Acne Vulgaris.

    Categories: 4-Quinolones, Heterocyclic Compounds, 2-RingProducts: MAGNIS %1 KREM ,30 G, AKNEFLOKS %1 KREM, 30 G
  7. Drug

    Desipramine

    go.drugbank.com/drugs/DB01151
    Approved

    TCAs also block histamine-H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred … See toxicity section below for a complete listing of side effects.

    Categories: Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor AntagonistsSynonyms: 5-(γ-methylaminopropyl)iminodibenzyl, N-(3-methylaminopropyl)iminobibenzyl
  8. Drug

    Fecal microbiota

    go.drugbank.com/drugs/DB17743
    ApprovedInvestigational

    [A259182,L46217,L46222] Although the incidence of CDI has declined and the number of cases requiring hospitalization has been lower over the years, the recurrence of CDI still represents a challenge. … Recurrent CDI has a high risk of mortality and a high failure rate.

  9. Drug

    Rosuvastatin

    go.drugbank.com/drugs/DB01098
    ApprovedInvestigational

    [A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality. … [A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular

    Mixtures: ROSUVINA LEGRAND® E 10/40, ROSUVINA LEGRAND® E 10/20Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  10. Drug

    Silicon

    go.drugbank.com/drugs/DB12982
    Approved

    Silicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or

    Mixtures: BLACKMORES teen multi for GIRLS capsule, C & D